539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in HumansJim Zheng, Winston C. Tse, John O. Link et al.|Open Forum Infectious Diseases|2018Cited by 15
Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance PathwayJim Zheng, Raju Subramanian, Bing Lu et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13
Discovery ofLenacapavir: First-in-Class Twice-YearlyCapsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, John O. Link, Winston C. Tse et al.|Journal of Medicinal Chemistry|2025Cited by 11